Study and Modeling of Perforator Flap Vascularization (EMoVaLP)
Status
Conditions
Treatments
Study type
Funder types
Identifiers
Details and patient eligibility
About
The aim of reconstructive surgery is to restore physical integrity altered by trauma, congenital malformations or cancerous pathologies. Several techniques are available, including flap surgery, which enables tissue to be moved from one anatomical location to another. Perforating skin/subcutaneous flaps are segments of skin and subcutaneous cellular tissue vascularized by a feeder vascular pedicle. This surgical technique has virtually zero donor-site morbidity, as it is no longer necessary to harvest muscle to ensure reliable vascularization of the flap.
Flap vascularization is a variable mechanism, complex to describe and understand. For cutaneous and subcutaneous (fatty) flaps, which account for the majority of flaps used, perforator flaps (vascularized by a subcutaneous perforator artery) have become the benchmark. Unfortunately, their vascularization is currently poorly understood, and depends on experimental work carried out on fresh cadaveric anatomical specimens. These cadaveric studies fail to take into account several key factors influencing perforasomes (perforasome: skin territory vascularized by a pedicle), namely body temperature, blood pressure, heart rate, intraoperative patient position and biological parameters.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age between 18 and 70
- Reconstructive surgery using pedicled perforating flap or free perforating flap.
- Flap with a surface area of at least 50 cm2 (in order to have a sufficiently large surface area for good perfusion visualization)
- Pedicled perforating flaps group: Patients with pelvic eschar
- Free perforating flaps group: Traumatic pathology of the lower and/or upper limb
Exclusion criteria
- No consent obtained
- No social security affiliation
- Persons under court protection
- Persons participating in another study with an exclusion period still in progress
Trial design
Primary purpose
Allocation
Interventional model
Masking
20 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Christian HERLIN, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal